Carboplatin
OncoPharm
00:00
Emetogenic classification and NK1 data
John explains recent studies showing benefit from NK1 antagonists at AUC≥4 and nuances about dexamethasone in control arms.
Play episode from 16:41
Transcript
John explains recent studies showing benefit from NK1 antagonists at AUC≥4 and nuances about dexamethasone in control arms.
